Compare MCY & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCY | BLCO |
|---|---|---|
| Founded | 1961 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.4B |
| IPO Year | 1995 | 2022 |
| Metric | MCY | BLCO |
|---|---|---|
| Price | $109.58 | $17.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $100.00 | $18.45 |
| AVG Volume (30 Days) | 252.3K | ★ 363.0K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $5,992,468,000.00 | $5,101,000,000.00 |
| Revenue This Year | $5.16 | $8.65 |
| Revenue Next Year | $5.59 | $5.59 |
| P/E Ratio | $32.12 | ★ N/A |
| Revenue Growth | ★ 9.44 | 6.47 |
| 52 Week Low | $65.77 | $13.09 |
| 52 Week High | $111.46 | $18.92 |
| Indicator | MCY | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 68.78 | 73.08 |
| Support Level | $84.77 | $16.26 |
| Resistance Level | N/A | $17.52 |
| Average True Range (ATR) | 2.78 | 0.45 |
| MACD | 0.58 | 0.24 |
| Stochastic Oscillator | 92.45 | 96.54 |
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The company offers the following types of automobile coverage: collision, property damage, bodily injury (BI), comprehensive, personal injury protection (PIP), underinsured and uninsured motorist, and other hazards. Additionally, it offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages. The company has one reportable business segment, the Property and Casualty business segment.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.